01:21 PM EDT, 04/10/2024 (MT Newswires) -- Telo Genomics ( TDSGF ) a biotech company developing a telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, on Wednesday said the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to TELO's laboratory at the MaRS Center in Toronto.

The accreditation was awarded after a recent on-site inspection as part of the CAP's Accreditation Programs.

Telo Genomics ( TDSGF ) shares were last seen up C$0.005 to $0.18 on the TSX Venture Exchange.

Price: 0.18, Change: +0.01, Percent Change: +2.86